Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
2(66.7%)
Phase 1
1(33.3%)
3Total
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04891809Phase 2Active Not Recruiting

Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM

Role: collaborator

NCT02560220Phase 1Completed

MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients

Role: collaborator

NCT03171389Phase 2Unknown

POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST

Role: collaborator

All 3 trials loaded